PT1423145E - Composicoes para o tratamento da doenca de parkinson contendo um antagonista do receptor cb1 e um produto que activa a neurotransmissao dopaminergica no cerebro - Google Patents

Composicoes para o tratamento da doenca de parkinson contendo um antagonista do receptor cb1 e um produto que activa a neurotransmissao dopaminergica no cerebro

Info

Publication number
PT1423145E
PT1423145E PT02772514T PT02772514T PT1423145E PT 1423145 E PT1423145 E PT 1423145E PT 02772514 T PT02772514 T PT 02772514T PT 02772514 T PT02772514 T PT 02772514T PT 1423145 E PT1423145 E PT 1423145E
Authority
PT
Portugal
Prior art keywords
neurotransmissain
parkinson
antagonist
brain
receptor
Prior art date
Application number
PT02772514T
Other languages
English (en)
Portuguese (pt)
Inventor
Benavides Jesus
Boccio Daniel
Henin Yvette
Piot-Grosjean Odile
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT1423145E publication Critical patent/PT1423145E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT02772514T 2001-08-29 2002-08-28 Composicoes para o tratamento da doenca de parkinson contendo um antagonista do receptor cb1 e um produto que activa a neurotransmissao dopaminergica no cerebro PT1423145E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0111200A FR2829028B1 (fr) 2001-08-29 2001-08-29 Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de

Publications (1)

Publication Number Publication Date
PT1423145E true PT1423145E (pt) 2006-09-29

Family

ID=8866792

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02772514T PT1423145E (pt) 2001-08-29 2002-08-28 Composicoes para o tratamento da doenca de parkinson contendo um antagonista do receptor cb1 e um produto que activa a neurotransmissao dopaminergica no cerebro

Country Status (16)

Country Link
US (2) US7217705B2 (enExample)
EP (2) EP1423145B1 (enExample)
JP (2) JP2005505551A (enExample)
AR (1) AR036302A1 (enExample)
AT (1) ATE328609T1 (enExample)
AU (2) AU2002337277B2 (enExample)
CA (1) CA2458348A1 (enExample)
CY (1) CY1105341T1 (enExample)
DE (1) DE60212148T2 (enExample)
DK (1) DK1423145T3 (enExample)
ES (1) ES2263816T3 (enExample)
FR (1) FR2829028B1 (enExample)
IL (2) IL160557A0 (enExample)
MX (1) MXPA04001645A (enExample)
PT (1) PT1423145E (enExample)
WO (1) WO2003020314A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004252109B2 (en) 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
JP2007522255A (ja) * 2004-02-17 2007-08-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 置換アゼチジン化合物、その製造および医薬品としての使用
ES2244314B1 (es) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
BRPI0613505A2 (pt) 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
BRPI0806312A2 (pt) 2007-01-04 2011-09-06 Prosidion Ltd agonistas cgpr piperidina
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
JP2010514828A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
PL2215072T3 (pl) * 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorficzna postać rotygotyny
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
EP2421848A1 (en) 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
EP2630139A1 (en) * 2010-10-22 2013-08-28 Janssen Pharmaceutica, N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US20250082586A1 (en) * 2021-05-21 2025-03-13 Brian Stuart Murphy Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
AU1732401A (en) * 1999-12-10 2001-06-18 Takeda Chemical Industries Ltd. Medicinal compositions for oral use
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation

Also Published As

Publication number Publication date
EP1423145A1 (fr) 2004-06-02
JP2010053153A (ja) 2010-03-11
IL193325A0 (en) 2009-02-11
DK1423145T3 (da) 2006-10-02
US20070197654A1 (en) 2007-08-23
ES2263816T3 (es) 2006-12-16
JP2005505551A (ja) 2005-02-24
CA2458348A1 (en) 2003-03-13
EP1649849A2 (fr) 2006-04-26
AU2002337277B2 (en) 2008-06-05
EP1423145B1 (fr) 2006-06-07
US20040209861A1 (en) 2004-10-21
AU2008212039A1 (en) 2008-10-09
FR2829028B1 (fr) 2004-12-17
IL160557A0 (en) 2004-07-25
DE60212148T2 (de) 2007-04-19
CY1105341T1 (el) 2010-03-03
US7217705B2 (en) 2007-05-15
EP1649849A3 (fr) 2006-11-02
MXPA04001645A (es) 2004-05-31
WO2003020314A1 (fr) 2003-03-13
ATE328609T1 (de) 2006-06-15
FR2829028A1 (fr) 2003-03-07
AR036302A1 (es) 2004-08-25
DE60212148D1 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
PT1423145E (pt) Composicoes para o tratamento da doenca de parkinson contendo um antagonista do receptor cb1 e um produto que activa a neurotransmissao dopaminergica no cerebro
AU2002337277A1 (en) Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
IL160558A0 (en) Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
CY2013041I1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
HUP0103558A3 (en) Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury
EP1418834A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
DE69912808D1 (de) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
KR102467285B9 (ko) 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물
AU2003248893A8 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.
AU2003277298A8 (en) Pharmaceutical compositions for treatment of parkinson's disease
AU2002341060A1 (en) Composition for treating Parkinson's disease containg a CB1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
AU2003230848A8 (en) Methods and compositions for treating alzheimer's disease